Investment Analysts’ Weekly Ratings Changes for Oscar Health (OSCR)

Several analysts have recently updated their ratings and price targets for Oscar Health (NYSE: OSCR):

• 9/18/2026 – Oscar Health had its price target raised by Raymond James Financial, Inc. from $34.00 to $42.00. They now have an “outperform” rating on the stock.
• 9/17/2026 – Oscar Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $48.00 price target on the stock.
• 9/17/2026 – Oscar Health had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $34.00 price target on the stock.
• 9/17/2026 – Oscar Health had its price target raised by Barclays PLC from $39.00 to $49.00. They now have an “overweight” rating on the stock.
• 9/17/2026 – Oscar Health had its price target raised by Bank of America Corporation from $28.00 to $30.00. They now have an “underperform” rating on the stock.
• 9/17/2026 – Oscar Health had its “equal weight” rating reaffirmed by Stephens. They now have a $34.00 price target on the stock.
• 9/17/2026 – Oscar Health had its price target raised by Robert W. Baird from $27.00 to $33.00. They now have a “neutral” rating on the stock.
• 8/13/2026 – Oscar Health had its price target raised by Wells Fargo & Company from $20.00 to $27.00. They now have an “equal weight” rating on the stock.
• 8/12/2026 – Oscar Health had its “mixed” rating reaffirmed by Wells Fargo & Company.
• 8/11/2026 – Oscar Health had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $30.00 price target on the stock.
• 8/11/2026 – Oscar Health was upgraded by Weiss Ratings from “sell (d+)” to “hold (c+)”.
• 8/7/2026 – Oscar Health was given a new $27.00 price target by Robert W. Baird.
• 8/7/2026 – Oscar Health had its price target raised by UBS Group AG from $20.00 to $26.00. They now have a “neutral” rating on the stock.
• 8/6/2026 – Oscar Health had its price target raised by Barclays PLC from $35.00 to $39.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Oscar Health

In other Oscar Health news, Director Mario Schlosser sold 600,000 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $30.34, for a total value of $18,204,000.00. Following the sale, the director directly owned 480,866 shares of the company’s stock, valued at approximately $14,589,474.44. This represents a 55.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Adam Mcananey sold 9,092 shares of Oscar Health stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total transaction of $285,943.40. Following the sale, the insider directly owned 209,004 shares of the company’s stock, valued at approximately $6,573,175.80. This trade represents a 4.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 874,451 shares of company stock valued at $26,761,671. 22.64% of the stock is currently owned by company insiders.

Oscar Health, Inc is a technology-driven health insurance company that provides health plans and related services to individuals, families and businesses in the United States. The company primarily serves members through plans offered under the Affordable Care Act (ACA), including individual and family coverage purchased through government marketplaces.

Oscar’s offerings include medical insurance plans with access to provider networks, prescription drug coverage and member support services.